These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


601 related items for PubMed ID: 18600596

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Incretin-based therapy and type 2 diabetes.
    Hare KJ, Knop FK.
    Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
    [Abstract] [Full Text] [Related]

  • 3. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B.
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [Abstract] [Full Text] [Related]

  • 4. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS.
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
    Ranganath LR.
    J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ, Vilsbøll T, Deacon CF.
    Mol Cell Endocrinol; 2009 Jan 15; 297(1-2):127-36. PubMed ID: 18786605
    [Abstract] [Full Text] [Related]

  • 10. The physiologic role of incretin hormones: clinical applications.
    Cefalu WT.
    J Am Osteopath Assoc; 2010 Mar 15; 110(3 Suppl 2):S8-S14. PubMed ID: 20382839
    [Abstract] [Full Text] [Related]

  • 11. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M, Bunck MC, Heine RJ.
    Ned Tijdschr Geneeskd; 2004 Sep 25; 148(39):1912-7. PubMed ID: 15495988
    [Abstract] [Full Text] [Related]

  • 12. The role of incretin on diabetes mellitus.
    Sanusi H.
    Acta Med Indones; 2009 Oct 25; 41(4):205-12. PubMed ID: 20737753
    [Abstract] [Full Text] [Related]

  • 13. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ, McGill MA.
    Clin Drug Investig; 2012 Jan 01; 32(1):1-14. PubMed ID: 21958333
    [Abstract] [Full Text] [Related]

  • 14. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J.
    Regul Pept; 2005 Jun 15; 128(2):149-57. PubMed ID: 15780434
    [Abstract] [Full Text] [Related]

  • 15. Extrapancreatic effects of GIP and GLP-1.
    Vella A, Rizza RA.
    Horm Metab Res; 2004 Jun 15; 36(11-12):830-6. PubMed ID: 15655715
    [Abstract] [Full Text] [Related]

  • 16. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK, Vilsbøll T, Holst JJ.
    Curr Protein Pept Sci; 2009 Feb 15; 10(1):46-55. PubMed ID: 19275672
    [Abstract] [Full Text] [Related]

  • 17. Beta-cell function and mass in type 2 diabetes.
    Larsen MO.
    Dan Med Bull; 2009 Aug 15; 56(3):153-64. PubMed ID: 19728971
    [Abstract] [Full Text] [Related]

  • 18. Mining incretin hormone pathways for novel therapies.
    Wideman RD, Kieffer TJ.
    Trends Endocrinol Metab; 2009 Aug 15; 20(6):280-6. PubMed ID: 19595611
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb 15; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 20. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C, Wright A, Chiquette E.
    Pharmacotherapy; 2006 Mar 15; 26(3):360-74. PubMed ID: 16503716
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 31.